Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Shipped under ambient temperature
CT-1812 is a first-in-class, orally available sigma-2/PGRMC1 antagonist (alpha beta oligomer receptor antagonist), is being developed by Cognition. CT-1812 is a novel therapeutic candidate for Alzheimer's disease.
Sun-shinechem(SSC) provides a wide range of research chemicals and biochemicals including novel life-science reagents, reference compounds, APIs, building blocks and Natural compounds for laboratory and scientific use.